ReviewSchizophrenia bulletin2017
A Transdiagnostic Review of Negative Symptom Phenomenology and Etiology.
Review in Schizophrenia bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The association between attachment insecurity and negative symptoms in clinical and non-clinical populations: A systematic review and meta-analysis.Psychology and psychotherapy · 2026Pooled it
- Peripheral blood immune markers associated with negative symptoms in first episode psychosis: a systematic review.Frontiers in psychiatry · 2026Pooled it
- From Memories of Past Experiences to Present Motivation? A Meta-analysis on the Association Between Episodic Memory and Negative Symptoms in People With Psychosis.Schizophrenia bulletin · 2022Pooled it
- Trait Anhedonia in Schizophrenia: A Systematic Review and Comparative Meta-analysis.Schizophrenia bulletin · 2022Pooled it
- Childhood premorbid adjustment as a marker for 20-year impairments in schizophrenia spectrum disorder: results from the OPUS study.European child & adolescent psychiatry · 2026Trial
- Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour.Nature communications · 2025Trial
- Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.Schizophrenia bulletin · 2022Trial
- Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT.Health technology assessment (Winchester, England) · 2021Trial
- Baseline psychopathology and relationship to longitudinal functional outcome in attenuated and early first episode psychosis.Schizophrenia research · 2019Trial
- Modifiable Predictors of Supported Employment Outcomes Among People With Severe Mental Illness.Psychiatric services (Washington, D.C.) · 2019Trial
- Motivation and pleasure deficits reflect altered network embedding of normal brain deviations in schizophrenia.Schizophrenia research · 2026Article
- Arginine-vasopressin systems in autistic phenotype schizophrenia: effect of a genetic variant of AVPR1a and AVPR1b.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Alpha Frequency Dysrhythmia in Treatment-Resistant Schizophrenia: Associations with EEG Background Changes, Disorganized Symptoms, and Dissociation.Biomedicines · 2026Article
- Value representation in youth psychopathology: evidence of a transdiagnostic risk mechanism for psychosis.Translational psychiatry · 2026Article
- Computational phenotypes underlying effort-based decision-making and negative symptoms in a transdiagnostic severe mental illness sample.Molecular psychiatry · 2026Article
- Negative symptoms and resting state functional connectivity: Leveraging ecological momentary assessment and individual-specific techniques.Schizophrenia research · 2026Article
- Facial expressions and emotional experience during social interaction in autism and schizophrenia.Schizophrenia (Heidelberg, Germany) · 2026Article
- Thalamic nuclei volumes across psychiatric and neurological disorders: a multi-site magnetic resonance imaging study.Translational psychiatry · 2026Article
- Blunted experience of pleasure, unsystematic subjective value representation, and disrupted goal-directed behaviors: an ecological momentary assessment study across mood and psychotic disorders.Schizophrenia bulletin · 2026Article
- Orbitofrontal Thickness and Network Associations as Transdiagnostic Signature of Amotivation Along the Bipolar-Schizophrenia Spectrum.Schizophrenia bulletin · 2026Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the DSM5, negative symptoms are 1 of the 5 core dimensions of psychopathology evaluated for schizophrenia. However, negative symptoms are not pathognomonic-they are also part of the diagnostic criteria for other schizophrenia-spectrum disorders, disorders that sometimes have comorbid psychosis, diagnoses not in the schizophrenia-spectrum, and the general "nonclinical" population. Although etiological models of negative symptoms have been developed for chronic schizophrenia, there has been little attention given to whether these models have transdiagnostic applicability. In the current review, we examine areas of commonality and divergence in the clinical presentation and etiology of negative symptoms across diagnostic categories. It was concluded that negative symptoms are relatively frequent across diagnostic categories, but individual disorders may differ in whether their negative symptoms are persistent/transient or primary/secondary. Evidence for separate dimensions of volitional and expressive symptoms exists, and there may be multiple mechanistic pathways to the same symptom phenomenon among DSM-5 disorders within and outside the schizophrenia-spectrum (ie, equifinality). Evidence for a novel transdiagnostic etiological model is presented based on the Research Domain Criteria (RDoC) constructs, which proposes the existence of 2 such pathways-a hedonic pathway and a cognitive pathway-that can both lead to expressive or volitional symptoms. To facilitate treatment breakthroughs, future transdiagnostic studies on negative symptoms are warranted that explore mechanisms underlying volitional and expressive pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.